We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.

Science (New York, N.Y.) | Apr 16, 1999

Mutation of the VHL tumor suppressor is associated with the inherited von Hippel-Lindau (VHL) cancer syndrome and the majority of kidney cancers. VHL binds the ElonginC-ElonginB complex and regulates levels of hypoxia-inducible proteins. The structure of the ternary complex at 2.7 angstrom resolution shows two interfaces, one between VHL and ElonginC and another between ElonginC and ElonginB. Tumorigenic mutations frequently occur in a 35-residue domain of VHL responsible for ElonginC binding. A mutational patch on a separate domain of VHL indicates a second macromolecular binding site. The structure extends the similarities to the SCF (Skp1-Cul1-F-box protein) complex that targets proteins for degradation, supporting the hypothesis that VHL may function in an analogous pathway.

Pubmed ID: 10205047 RIS Download

Mesh terms: Amino Acid Sequence | Binding Sites | Cell Cycle Proteins | Cloning, Molecular | Crystallography, X-Ray | Genes, Tumor Suppressor | Humans | Hydrogen Bonding | Ligases | Models, Molecular | Molecular Sequence Data | Mutation | Mutation, Missense | Neoplasms | Protein Conformation | Protein Folding | Protein Structure, Secondary | Proteins | S-Phase Kinase-Associated Proteins | Surface Properties | Transcription Factors | Tumor Suppressor Proteins | Ubiquitin-Protein Ligases | Von Hippel-Lindau Tumor Suppressor Protein | von Hippel-Lindau Disease